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ABSTRACT 
Transdermal drug delivery system has been developed or being developed to vanquish the downsides associated with conventional strategies as 
it avoids first pass hepatic metabolism, improved patient compliances, easy termination of therapy, possibility of self-administration etc. The 
main challenge in designing transdermal patch is to overcome the low permeability of skin. Several strategies have been developed to overcome 
the barrier properties and to enhance the transportation of drug molecules across the skin. In the last decades numerous transdermal patches 
fabricated from polysaccharides have been reported. There has been a growing interest in using chitosan in transdermal formulations thanks to 
their biocompatibility, non-toxicity, film forming ability, non- skin irritancy etc. This article highlights the application of chitosan in the 
development of transdermal drug delivery systems such as microneedles, films etc.  
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INTRODUCTION 
Conventional route of drug delivery while commonly 
employed have several drawbacks that may be effectively 
overcome by non-conventional routes. These approaches 
may appear fascinating relative to the expense and duration 
for the development of new drug molecules. Among several 
non-conventional approaches that have been tried with 
varying level of success transdermal route is attractive. For 
several years substantial research has been devoted to 
transdermal drug delivery system. The main benefits of 
transdermal route include prevents first pass liver effect, 
easy termination of therapy, possibility of painless therapy, 
prevents the intervention of intestinal and gastric fluids etc 1. 
However the protective barrier properties of the skin 
remarkably reduce the permeation of drugs molecules 
across the skin 2. For transdermal therapy to be potential, 
the drug molecules have to reach the vasculature in desired 
amounts to generate a therapeutic effect. In the recent 
decade’s substantial research have been conducted to 
develop potential transdermal device which can effectively 
transport drug molecules across the skin. The present article 
detailed the application of chitosan in the fabrication of 
effective transdermal drug delivery system. 
Among several polysaccharides, chitosan is one of the chief 
commercially significant biodegradable polymer from a 
pharmaceutical point of view. Chitosan is a distinct cationic 
polysaccharide and is different from other polysaccharides 
in the perspective that cationic character is absent in other 
polysaccharides. The polycation polymer contains 
glucosamine and N-acetyl glucosamine units linked together 
through β-(1-4) glycosidic bonds. The structure of chitosan is 
displayed in Figure.1. Chitosan is obtained by the alkaline 
deacetylation of N-acetyl glucosamine polymer, chitin which 
is the major building constituent of shrimp and crab shell 3. 
The application of chitosan is restricted as it is insoluble in 
water. However it is soluble in dilute acids including formic 
acid, acetic acid, lactic acid etc. The presence of remarkable 
nitrogen content makes chitosan a commercially fascinating 
polymer as it can act as a chelating agent 4. 
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Figure 1: Structure of chitosan 5 
 
Currently graft polymerization approach is employed on 
pristine chitosan to enhance the existing properties and to 
incorporate required features for specific applications 3. 
Chitosan displays several biological activities including 
cholesterol lowering, antihypertension and immune 
response activity. The enhanced attention of chitosan 
especially in the biomedical field is because of its exceptional 
properties including non-cytotoxicity, biocompatibility, 
capacity to interact with certain organic compounds, 
biodegradability, susceptibility to enzymatic hydrolysis and 
non-allergenic behavior 6. These behaviors are mainly 
beneficial to several biological applications such as wound 
healing, tissue engineering and drug delivery. In addition to 
the detailed properties, the excellent film forming ability and 
non-skin irritatancy encouraged several research groups to 
explore CS in TD drug delivery system. Although several 
research group utilized CS as a TD drug delivery platform, 
there are many opportunities which required to be 
investigated.  
TRANSDERMAL PATCHES FROM CHITOSAN 
Allena et al fabricated a transdermal patch composed of 
chitosan and hydroxypropyl methyl cellulose for the delivery 
of metformin hydrochloride across the skin 7. Dibutyl 
phthalate was incorporated as plasticizer. The device 
displayed better tensile strength and folding endurance. The 
release of metformin hydrochloride from the device followed 
zero order kinetics and non-fickian diffusion mechanism. 
The investigation revealed that the device with 
hydroxypropyl methyl cellulose : chitosan in the ratio 1:5 
together with dibutylphthalate was efficient to transport 
metformin hydrochloride.  
Ali et al developed a transdermal device by adding 
glibenclamide nanocrystal and microcrystal into chitosan 
solution 8. The patch showed satisfactory physicochemical 
properties without significant agglomeration of 
glibenclamide particles during the processing steps. After 24 
hours, glibenclamide nanosystem and microsystem, 
respectively released 85 ± 3.1 and 61 ± 3.9 % glibenclamide. 
Furthermore glibenclamide nanosystem and microsystem 
showed 498 ± 33.35 and 362 ± 25.5 µg/cm2 cumulative 
permeation, respectively in 24 hours. In addition, cumulative 
flux of 23.14 and 13.64 µg/cm2/h was shown by nanosystem 
and microsystem, respectively. In vivo test undoubtedly 
displayed the superior capacity of the nanosystem to 
decrease glucose level of blood. The article firmly stated that 
the glibenclamide nanosystem have the potential to maintain 
greater concentration of drug for long time.  
Balamurugal and Agrawal prepared chitosan based 
transdermal patch for the skin transportation of lisinopril by 
solvent evaporation strategy without adding permeation 
enhancers 9. The lisinopril-polymer incompatibility was 
confirmed using DSC and FTIR mapping. In vitro skin 
penetration tests were carried out on rat skin and cadaver 
skin, which revealed that the patch followed Higuchi kinetics 
with diffusion mediated lisinopril release. The safety of the 
patch was studied using in vivo skin irritation assays which 
displayed no sign of irritability.   
Behin et al developed a transdermal patch for the delivery of 
glipizide which is commonly used for type 2 diabetes 
treatments 10. They first prepared an inclusion complex of 
glipizide and β cyclodextrin and the complex was 
incorporated into chitosan matrix. The patch containing 1.5 
% w/v chitosan displayed the highest glipizide content of 
97.65 %. After 24 hour 96 % of glipizide was released from 
the patch. The thickness and folding endurance of the 
formulation increased with increase in chitosan 
concentration. The glipizide release followed Higuchi plot 
with diffusion controlled pattern. Skin irritation assay 
showed the non-toxicity of the patch. The ex-vivo test 
showed constant glipizide permeation for long periods.  
Can et al fabricated transdermal device of ondansetron using 
chitosan as matrix and 2-(2-ethoxy-ethoxy)ethanol 
(Transcutol) as plasticizer 11. They studied the effect of 
terpenes such as nerolidol, eucalyptol and limonene on the 
skin permeation of drug molecules. FTIR mapping was 
carried out to study the impact of chitosan membrane 
formulation on the in vitro conformational order of lipid 
layers. The outcomes revealed that the patch composed of 
transcutol and terpenes could be employed to fabricate 
ondansetron transdermal patches. Compared to other 
terpenes eucalyptol displayed the highest skin permeation 
enhancing effect. 
Sarkar et al prepared novel transdermal patch composed of 
cellulose nanofibrils and chitosan to transport ketorolac 
tromethamine efficiently across the skin 12. The cellulose 
nanofibrils were prepared from jute fibres. FTIR mapping 
confirmed the efficient loading of drug molecules in the 
matrix. The XRD profile revealed the crystalline nature of the 
prepared transdermal membranes. The drug release pattern 
from the device suggested that the release rate of ketorolac 
tromethamine was sustained after the addition of cellulose 
nanofibrils. 
Cui et al reported about transdermal patch from chitosan 
and polyvinyl alcohol by elctrospinning strategy 13. 
Glutaraldehyde was used as crosslinker for the developed 
composite nanofibres. They reported that no destruction in 
the morphology of the nanofibre was observed after 
crosslinking. The thermomechanical properties of the 
material were remarkably improved after crosslinking 
ascribed to the formation of network structure. Drug release 
tests proved that crosslinked device displayed no burst 
release profile and followed Fickian diffusion mechanism. 
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Another research group developed chitosan-gelatin 
composite membrane and examined its potential for the 
transdermal delivery of theophylline 14. SEM images revealed 
that the drug molecules were homogeneously distributed in 
the matrix. FTIR and DSC analysis confirmed that there 
existed only weak interaction between drug and polymer. In 
vitro skin permeation test proved that up to around 6 hour, 
only moderate changes on theophylline release pattern was 
observed with increased concentration of gelatin in the 
device. However the release rate of theophylline was 
improved at higher release time with increased gelatin 
content, ascribed to the enhanced swellability of the 
membrane. The theophylline release followed non-Fickian 
mechanism. 
Hemant and Shivakumar fabricated chitosan acetate 
membrane to transport propranolol hydrochloride across 
the skin 15. They modified chitosan acetate with 
acetaldehyde and the content was loaded with propranolol 
hydrochloride. Drug content in the patch was about 0.9 to 1.4 
mg/cm2. The release of propranolol hydrochloride was 
significantly higher in chitosan acetate compared to pristine 
chitosan. The permeability coefficient for chitosan and 
chitosan acetate was respectively, 0.97 x 104 and 6.12 x 10-4 
gcm2/day. They reported that FTIR and DSC analysis showed 
the absence of drug-polymer interaction. Kashinatha et al 
prepared valsartan loaded modified chitosan for the 
transdermal drug delivery. They modified chitosan with 
acetaldehyde and glycerin was added as plasticizer 16. They 
reported that valsartan permeation was increased with 
increase in glycerin content, especially at chitosan 
concentration of 20 to 30 % w/w. However further addition 
of plasticizer did not remarkably enhanced drug permeation. 
Stability assay suggested that the devices were stable. 
Kim et al developed silver hybridized chitosan device to 
deliver drug molecules across the skin 17. They reported that 
the patch prepared from 3 % silver nitrate, 1 % chitosan and 
0.003 % sodium borohydride showed enhanced tensile 
strength and drug delivery potential. The release of drug 
molecules was enhanced due to the increase in silver 
content. Compared to pure chitosan, the developed device 
could transport drug molecules 1.5 times faster. Kim et al 
prepared another transdermal device based on chitosan and 
poly(L-3,4-dihydroxyphenyl alanine) 18. Drug molecules 
were quickly released from the developed poly(L-3,4-
dihydroxyphenyl alanine) filled chitosan device when 
compared with pristine chitosan. 
Maji et al fabricated maleic anhydride cross-linked polyvinyl 
alcohol-chitosan device for the transdermal delivery of 
alprazolam 19. The absence of drug-polymer interaction was 
confirmed using FTIR. The drug permeability was 
remarkably enhanced with increase in polyvinyl alcohol 
content. The alprazolam release followed Higuchi kinetics. 
Furthermore the diffusion coefficient was found to be 
around 0.5 suggesting Fickian diffusion. Skin irritation test 
showed that the patches were non-toxic. Ramesh and 
Sireesha dispersed chitosan nanoparticles in carbopol gel 
and evaluated its potential to transport ramipril across the 
skin 20. FTIR and DSC analysis confirmed the absence of 
interaction between drug and polymer. The drug release 
followed first order kinetics with diffusion controlled 
mechanism. 
Sadasival et al prepared transdermal device of insulin based 
on chitosan and tripolyphosphate based ionotropic gelation 
strategy 21. The developed nanoparticles displayed size 
range of 465 and 661 nm with enhanced drug encapsulation 
efficiency. Controlled release transdermal devices were 
prepared by the combination of chitosan with hydroxypropyl 
methylcellulose, polyvinyl pyrrolidone K30 and polyethylene 
glycol 400. The drug release improved with the increase in 
content of hydrophilic polymers. 
Shinde et al fabricated transdermal devices using 
hydroxypropyl methylcellulose, chitosan and eudragit RL-
100 22. To improve the permeability an inclusion complex 
with hydroxypropyl-β-cyclodextrin was also prepared. They 
studied the effect of oleic acid and propylene glycol on 
transdermal drug delivery. Device containing eudragit 
showed the highest folding endurance. Furthermore, the 
tensile strength was enhanced with increase in eudragit 
content. Drug release studies showed that the release of drug 
was sustained with increasing the content of eudragit in the 
device. The device incorporated with inclusion complex of 
drug displayed enhanced permeation when compared with 
device incorporated with plain drug. Finally they reported 
that hydroxypropyl-β-cyclodextrin in conjugation with 
chemical penetration enhancers such as oleic acid and 
propylene glycol displayed a higher permeation flux. 
Siddaramaiah et al prepared chitosan and hydroxypropyl 
methylcellulose blends in different composition 23. Glycerine 
was used as plasticizer. The mechanical properties increased 
with increasing composition of hydroxypropyl 
methylcellulose. The device possessed improved 
transparency. The drug molecules were homogeneously 
dispersed in the matrix. They evaluated the potential of the 
device to transport propranolol hydrochloride. Thakur et al 
fabricated chitosan and montmorillonite composite 
membranes for the transdermal drug delivery 24. Swelling 
ratios and water uptake of the device was reduced with 
increase in montmorillonite content. The addition of 
montmorillonite increased the tensile strength and 
decreased the extensibility, ascribed to the creation of 
intercalated structure and reduction in mobility of polymer 
chain segments. They reported that the prepared device 
could efficiently deliver curcumin across the skin. 
Varshosaz et al prepared lidocaine loaded device with 
different molecular weight and concentration of chitosan 25. 
Lecithin was employed as permeation enhancer. The 
bioadhesion of the device was reduced with increasing 
concentration of chitosan. The drug release rate was 
enhanced with increasing the molecular weight and 
concentration of chitosan ascribed to the improvement on 
lidocaine-chitosan repulsion. The lidocaine flux was higher 
for 3 % high molecular weight chitosan gel compared to 
standard gel. Venugopal et al prepared insulin encapsulated 
chitosan nanoparticles for transdermal delivery 26. The 
developed device efficiently transported insulin across the 
skin as revealed by the remarkable reduction in plasma 
glucose level. 
MICRONEEDLES FROM CHITOSAN 
Chen et al in an article stated that it is necessary to reduce 
the dosage needed for vaccination especially in the case of 
epidemic emergencies 27. They examined the capacity of 
microneedles fabricated from chitosan for low-dose 
immunization. The device was composed of antigen loaded 
chitosan microneedles and polyvinyl alcohol/polyvinyl 
pyrrolidone supporting array patch. Polyvinyl alcohol and 
polyvinyl pyrrolidone furnished additional strength to attain 
superior microneedle insertion into the skin. The insertion of 
the device permitted a sustained antigen (ovalbumin) 
release for up to 28 days. They observed that rats applied 
with devices with low-dose antigen had persistently high 
antibody levels for 18 weeks, superior to intramuscular 
injection. Furthermore ovalbumin embedded chitosan 
microneedle had higher immunogenicity compared to 
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ovalbumin added chitosan solution. The investigation 
revealed that the developed device could efficiently deliver 
antigens across the skin. 
Chen and coworkers developed another microneedle device 
based on chitosan for the transportation of macromolecules 
28 They reported that the device possessed excellent tensile 
properties to be applied on rat skin. It pierces porcine skin 
and rat skin of depth around 250 and 200 µm, respectively. 
They employed bovine serum albumin as model 
macromolecule to evaluate the capacity of developed patch. 
In vitro drug release test displayed that the patch could 
furnish a sustained release of molecules for 8 days. Confocal 
studies revealed that the macromolecules could diffuse 
across the skin through the punctured areas produced by the 
microneedle. Furthermore the incorporation of bovine 
serum albumin in the patch did not change its secondary 
structure.  
The same research group used chitosan for the fabrication of 
microneedle which could be used for vaccination 29. They 
also incorporated poly(L-lactide-D,L-lactide) in the device 
for supporting as it furnished excellent tensile properties. 
The device pierce skin to around 600 µm depth which is 
necessary for the delivery of antigens to antigen presenting 
cells. Ovalbumin was employed as model antigen. They 
reported that the application of ovalbumin loaded 
microneedle in rat skin produced remarkably higher 
ovalbumin-specific antibody response which continued for 
around 6 weeks. 
Marin et al prepared microneedles from 
carboxymethycellulose and chitosan 30. The fabrication was 
performed under condition that helped the formation of 
polyelectrolyte complex based on the electrostatic 
interaction by oppositively charged carboxymethycellulose 
and chitosan. They reported that the device showed 
decreased hydration. Protein release test displayed that 
chitosan coating remarkably affected the release profile. 
Justin et al fabricated microneedle patch based on chitosan 
and grapheme quantum dots 31. The developed chitosan-
grapheme quantum dots nanocomposite displayed low 
cytotoxicity. Further, fluoresce blue in the presence of UV 
light, permitted the tracking of drug molecules attached on 
grapheme quantum dots by fluorescent imaging. They 
reported that the addition of 0.25-2.0 wt% of graphene 
quantum dots in the device remarkably enhanced the 
electrical conductivity. The device incorporated with 1 % 
grapheme quantum dots possessed enough mechanical 
strength to pierce across the skin. The device showed 
improved drug release profile compared to microneedle 
prepared from chitosan alone. Furthermore the device could 
deliver drugs with high molecular weight through 
iontophoresis.  
CONCLUSION 
In this article we investigated the applicability of chitosan in 
formulating transdermal drug delivery systems. The study 
clearly indicated that it is feasible to transport 
therapeutically effective amount of drug molecules across 
the skin using transdermal devices prepared from chitosan. 
Chitosan is efficient to transport both small and large 
molecular weight therapeutics. At the same time more 
investigation are to be required to further improve the 
potential of chitosan based devices.  
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